Neurolixis Inc. has been awarded a second supplemental research grant by the Michael J. Fox Foundation for Parkinson's Research (MJFF) to complete the study of biased and unbiased 5-HT1A agonists for the treatment of levodopa-induced dyskinesia in animal models of Parkinson's disease (PD).
The new grant will allow Neurolixis to further characterise its exceptionally-selective and efficacious serotonin 5-HT1A receptor agonists in models of dyskinesia. This is a common side-effect experienced by many Parkinson's disease patients treated with the antiparkinsonian agent, levodopa. If the new studies are successful, Neurolixis aims to take its clinical candidate, NLX-112, into proof-of-concept Phase 2 trials.
Read the Michael J Fox Foundation announcement.